Report Scope:

This report discusses the implications of stem cell research and commercial trends in the context of the current size and growth of the pharmaceutical market, both in global terms and analyzed by the most important national markets. The important technologies supporting stem cells are reviewed, and the nature and structure of the stem cell industry is discussed, with profiles of the leading companies, including recent merger and acquisition (M&A) activity. Five-year sales forecasts are provided for the national markets and the major therapeutic categories of the products involved.

Report Includes:

  • 18 data tables and 14 additional tables
  • An up-to-date overview and analysis of the global markets for (biological) stem cells and related products
  • Analyses of the global market trends, with historic revenue data for 2021, estimates for 2022 and 2023, and projections of compound annual growth rates (CAGRs) through 2027
  • Estimation of the actual market size and revenue forecast for global stem cells market in USD million terms, and corresponding market share analysis by product, application, end user, and region
  • Highlights of emerging technology trends, market opportunities and deterrents estimating current and future demand of stem cells related products and their derivatives for drug discovery
  • Discussion of market dynamics that impact the growth of the market for biological stem cells, clinical applications, market regulations, industry structure, and penetration of technologies within the biotech industry
  • Review of the patents and patent applications on stem cell research, and corresponding research/scientific publications during the analysis period
  • Competitive landscape of the key manufacturers and suppliers of the stem cell-related drug market, their product portfolios, financial updates, and major growth strategies within the marketplace
  • Company profiles of major players within the industry, including 3-D Matrix Medical Technology, International Stem Cell Corp., ReNeuron Group, and U.S. Stem Cell Inc.